Deregulated PI3K signalling in breast cancer has frequently been attributed to gain-of-function mutations in PIK3CA gene, encoding the PI3K p110α and/or to loss-of-function mutations in the PTEN gene6,31–35. This evidence concerns the gene PIK3CA and breast cancer.